Literature DB >> 22350698

Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production.

Kosuke Tsutsumi1, Takao Ohtsuka, Yasuhisa Mori, Minoru Fujino, Takaharu Yasui, Shinichi Aishima, Shunichi Takahata, Masafumi Nakamura, Tetsuhide Ito, Masao Tanaka.   

Abstract

BACKGROUND: Because of the rarity and variety of pancreatic neuroendocrine tumors (PNETs), there have been few reports regarding the indication for lymph node dissection in patients with these tumors. This study aimed to evaluate the risk of lymph node metastasis of PNETs based on the tumor size and hormonal production.
METHODS: Data for a total of 66 patients who had PNETs resected at our department between 1987 and 2010 were retrospectively studied. The clinicopathological features, including the disease-specific survival rate, were assessed based on the status of lymph node metastasis at the time of initial surgical resection. Then the cut-off point of tumor size to predict lymph node metastasis was estimated.
RESULTS: There were 12 patients (18%) with lymph node metastasis. The frequency of lymph node metastasis tended to be higher in gastrinomas than that in other tumors (43 vs. 15%; P = 0.08). The size of PNETs with lymph node metastasis was significantly larger than that of the PNETs without metastasis (P = 0.04). The postoperative survival rate in the PNET patients with lymph node metastasis was significantly lower than that in the patients without metastasis (P < 0.0001). Only 2 (8%) of 26 PNETs with a tumor size of <15 mm had lymph node metastasis, and both of these were gastrinomas. On the other hand, 10 (25%) of the remaining 40 PNETs with a tumor size of ≥15 mm had lymph node metastasis. Notably, there were no PNETs with lymph node metastasis in 22 non-gastrinomas with a tumor size of <15 mm.
CONCLUSIONS: Non-gastrinomas with a tumor size of ≥15 mm and all gastrinomas would be an indication for pancreatectomy with lymph node dissection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350698     DOI: 10.1007/s00535-012-0540-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  Endoscopic ultrasound-guided fine needle aspiration cytology of pancreatic neuroendocrine tumours: cytomorphological and immunocytochemical evaluation.

Authors:  F Chang; C Vu; A Chandra; J Meenan; A Herbert
Journal:  Cytopathology       Date:  2006-02       Impact factor: 2.073

2.  NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.

Authors:  Orlo H Clark; Al B Benson; Jordan D Berlin; Michael A Choti; Gerard M Doherty; Paul F Engstrom; John F Gibbs; Martin J Heslin; Anne Kessinger; Matthew H Kulke; Larry Kvols; Riad Salem; Leonard Saltz; Manisha H Shah; Stephen Shibata; Jonathan R Strosberg; James C Yao
Journal:  J Natl Compr Canc Netw       Date:  2009-07       Impact factor: 11.908

3.  Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form.

Authors:  F Gibril; D J Venzon; J V Ojeaburu; S Bashir; R T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

4.  Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.

Authors:  R Bettini; L Boninsegna; W Mantovani; P Capelli; C Bassi; P Pederzoli; G F Delle Fave; F Panzuto; A Scarpa; M Falconi
Journal:  Ann Oncol       Date:  2008-01-21       Impact factor: 32.976

Review 5.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

6.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

7.  The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases.

Authors:  J Soga; Y Yakuwa
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998

8.  Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Authors:  Karl Y Bilimoria; Mark S Talamonti; James S Tomlinson; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

9.  Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.

Authors:  Naohiro Nomura; Tsutomu Fujii; Naohito Kanazumi; Shin Takeda; Shuji Nomoto; Hideki Kasuya; Hiroyuki Sugimoto; Suguru Yamada; Akimasa Nakao
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-04-14

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  28 in total

Review 1.  Surgical resection of neuroendocrine tumors of the pancreas (pNETs) by minimally invasive surgery: the laparoscopic approach.

Authors:  Tomoki Shirota; Yuichi Nagakawa; Yatsuka Sahara; Chie Takishita; Yosuke Hijikata; Yuichi Hosokawa; Tetsushi Nakajima; Hiroaki Osakabe; Kenji Katsumata; Akihiko Tsuchida
Journal:  Gland Surg       Date:  2018-02

2.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

3.  Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis.

Authors:  Yusuke Kurita; Kazuo Hara; Takamichi Kuwahara; Nobumasa Mizuno; Nozomi Okuno; Shin Haba; Masataka Okuno; Seiji Natsume; Yoshiki Senda; Kensuke Kubota; Atsushi Nakajima; Yasumasa Niwa; Yasuhiro Shimizu
Journal:  J Gastroenterol       Date:  2019-12-19       Impact factor: 7.527

Review 4.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

5.  A Retrospective Analysis of Preoperative Evaluation and Surgical Resection for Metastatic Tumors of the Pancreas.

Authors:  Yuhei Endo; Hiroshi Noda; Fumiaki Watanabe; Takaharu Kato; Nao Kakizawa; Kosuke Ichida; Naoya Kasahara; Toshiki Rikiyama
Journal:  Indian J Surg Oncol       Date:  2019-03-18

6.  Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).

Authors:  Yassar M Hashim; Kathryn M Trinkaus; David C Linehan; Steven S Strasberg; Ryan C Fields; Dengfeng Cao; William G Hawkins
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

7.  Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group.

Authors:  Katiuscha Merath; Fabio Bagante; Eliza W Beal; Alexandra G Lopez-Aguiar; George Poultsides; Eleftherios Makris; Flavio Rocha; Zaheer Kanji; Sharon Weber; Alexander Fisher; Ryan Fields; Bradley A Krasnick; Kamran Idrees; Paula M Smith; Cliff Cho; Megan Beems; Carl R Schmidt; Mary Dillhoff; Shishir K Maithel; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2018-02-15       Impact factor: 3.454

8.  Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Authors:  Joo Young Kim; Jacqueline A Brosnan-Cashman; Soyeon An; Sung Joo Kim; Ki-Byung Song; Min-Sun Kim; Mi-Ju Kim; Dae Wook Hwang; Alan K Meeker; Eunsil Yu; Song Cheol Kim; Ralph H Hruban; Christopher M Heaphy; Seung-Mo Hong
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

9.  Predictive value of the Ki67 index for lymph node metastasis of small non-functioning pancreatic neuroendocrine neoplasms.

Authors:  Toshihiko Masui; Asahi Sato; Kenzo Nakano; Yuichiro Uchida; Akitada Yogo; Takayuki Anazawa; Kazuyuki Nagai; Yoshiya Kawaguchi; Kyoichi Takaori; Shinji Uemoto
Journal:  Surg Today       Date:  2019-03-05       Impact factor: 2.549

10.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.